Evaluation of an Innovative Over-the-Counter Treatment for Symptoms of Reflux Disease: Quick-Dissolving Alginate Granules. (23rd December 2012)

• Record Type: Journal Article
• Authors: Strugala, Vicki; Dettmar, Peter W.; Thomas, Edward C. M.
• Other Names: Fullas F. Academic Editor.; Murata Y. Academic Editor.; Ragno G. Academic Editor.
• Is Part Of: ISRN pharmaceutics. Volume 2012(2012)
• Publication Date: 2012-12-23
• Subjects: Pharmacy -- Periodicals; Pharmacological Phenomena; Pharmacology; Pharmacy; Electronic journals; Periodical; Periodicals; 615
• DOI: 10.5402/2012/950162
• Languages: English
• ISSNs: 2090-6145

Abstract

Abstract : Traditional antacids and alginate-based reflux suppressants are OTC products commonly used to treat reflux symptoms. There has been a lack of innovation of new formulations in this therapy area despite consumers finding established products unpalatable. Here we evaluate a novel product formulation which takes the form of quick-dissolving alginate granules in single-dose sachets (Gaviscon Direct Powder (GDP)). Market research and taste evaluation confirmed that reflux sufferers considered GDP to have good flavour and taste, no chalky aftertaste and dissolved rapidly in the mouth with 68% noting so within 10 seconds. GDP was considered convenient and easy to use. The consumer-driven product development was also shown to form a strong alginate raft in standardised in vitro conditions that met the specifications of the BP monograph (raft strength > 7.5 g). Gastric retention of GDP and a test meal was investigated in healthy volunteers using gamma scintigraphy in comparison to Liquid Gaviscon. Both products formed an alginate raft in the stomach above the test meal and emptied after the meal. The gastric retention of the GDP product was found to be noninferior to Liquid Gaviscon. In conclusion, the innovative GDP product formed an effective raft and was well liked by consumers.